Disease · HP_0002150
Hypercalciuria
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Hypercalciuria. Diseases, record HP_0002150. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002150
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Hypercalciuria
- Open Targets ID
- HP_0002150
- Other names
- Elevated urine calcium levels, Hypercalcinuria
- Highest stage of its drugs
- Approval, for 1 of its 9 drugs, from TTD
Source Open Targets
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CELLULOSE SODIUM PHOSPHATE | CHEMBL1201457 | Approval | TTD | 1 | 0 | 0 | Drugs and targets | |
| AMILORIDE | CHEMBL945 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CORTICOTROPIN | CHEMBL1201610 | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| HYDROCHLOROTHIAZIDE | CHEMBL435 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ESTRADIOL | CHEMBL135 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUCONAZOLE | CHEMBL106 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIFAMPIN | CHEMBL374478 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CHOLECALCIFEROL | CHEMBL1042 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SPIRONOLACTONE | CHEMBL1393 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets8
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha agonist | Phase 2 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| MC2R | Adrenocorticotropic hormone receptor | 1 | Melanocortin receptor 2 agonist | Phase 2/3 | https://conductscience.org/library/genes/4158 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 1 | Mineralocorticoid receptor antagonist | Unknown | https://conductscience.org/library/genes/4306 | Drugs and targets |
| SCNN1A | Amiloride-sensitive sodium channel, ENaC | 1 | Amiloride-sensitive sodium channel, ENaC blocker | Phase 2/3 | https://conductscience.org/library/genes/6337 | Drugs and targets |
| SCNN1B | Amiloride-sensitive sodium channel, ENaC | 1 | Amiloride-sensitive sodium channel, ENaC blocker | Phase 2/3 | https://conductscience.org/library/genes/6338 | Drugs and targets |
| SCNN1G | Amiloride-sensitive sodium channel, ENaC | 1 | Amiloride-sensitive sodium channel, ENaC blocker | Phase 2/3 | https://conductscience.org/library/genes/6340 | Drugs and targets |
| SLC12A3 | Solute carrier family 12 member 3 | 1 | Thiazide-sensitive sodium-chloride cotransporter inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6559 | Drugs and targets |
| VDR | Vitamin D3 receptor | 1 | Vitamin D receptor agonist | Unknown | https://conductscience.org/library/genes/7421 | Drugs and targets |
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01928082 | The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass | Phase 2 | 1 | 2018-03-07 | Hypercalciuria, Hypercalciuria, Familial Idiopathic, Osteopenia, Osteoporosis | ESTRADIOL | Its record names the disease | ClinicalTrials.gov |
| NCT02975492 | Assessing the Impact of a Mode of Vitamin D Supplementation (Sequential Dose vs Daily Dose) on the Incidence of Hypercalciuria in Subjets Aged From 2 to 18 Years | Not applicable | 280 | Transient Hypercalciuria | CHOLECALCIFEROL | Its record names the disease | ClinicalTrials.gov | |
| NCT03301038 | Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria | Phase 2 | 60 | Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia, Idiopathic Infantile Hypercalcemia - Mild Form, Hypercalciuria | RIFAMPIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04495608 | Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels | Phase 2 | 56 | Nephrolithiasis, Nephrocalcinosis, Hypercalciuria | FLUCONAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT00276289 | Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics | Not applicable | 10 | Idiopathic Hypercalciuria, Hypokalemia Caused by Thiazide Diuretics | SPIRONOLACTONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00638482 | Dose-Dependent Effect of Thiazide in Dent's Disease Hypercalciuria | Phase 2/3 | 10 | Dent's Disease, Nephrolithiasis | AMILORIDE, HYDROCHLOROTHIAZIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01349764 | Effect of Vitamin D Replacement in Patients With Urolithiasis | 10 | Urolithiasis | CHOLECALCIFEROL | Its record names the disease | ClinicalTrials.gov | ||
| NCT02155803 | ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study | Phase 2/3 | 10 | Sarcoidosis, Hypercalcemia Due to Sarcoidosis | CORTICOTROPIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002150
GET https://conductscience.org/api/diseases/v1/HP_0002150/drugs